Patients with psoriatic arthritis consistently identify nonjoint symptoms such as dactylitis, psoriasis, and uveitis, demonstrating the clinical utility of patient-reported outcome measures.
A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.
JAK inhibitor therapy targets inflammation and correlates with improvements in carotid artery measurements, while baseline vascular markers continue to predict cardiovascular risk.
A recent study reveals significant treatment response improvements in severe psoriatic arthritis and extensive psoriasis, emphasizing the need for personalized treatment strategies and sensitive outcome measures. (Source: Psoriatic Arthritis Research Consortium)